Bicycle Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bicycle Therapeutics (BCYC).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

3S.Buy

6Buy

3Hold

Consensus RatingMarket Outperform# Analysts12Avg. Consensus PT$20Upside to Avg. PT+397.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 30, 2026	Needham	Ami Fadia	PT Cut	Buy	$15→$14
Apr 8, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$13→$12
Mar 18, 2026	Oppenheimer	Jay Olson	PT Cut	Outperform	$44→$36
Mar 18, 2026	RBC Capital	Leonid Timashev	PT Cut	Sector Perform	$11→$7
Mar 18, 2026	Citizens	Brett Knoblauch	PT Cut	Market Outperform	$12→$8
Mar 18, 2026	Needham	Ami Fadia	PT Cut	Buy	$24→$15
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Hold	$10
Oct 31, 2025	Citizens	Reni Benjamin	PT Raise	Market Outperform	$10→$12
Oct 31, 2025	RBC Capital	Leonid Timashev	Downgrade	Outperform→Sector Perform	$27→$11
Aug 12, 2025	JMP Securities	Reni J. Benjamin	PT Cut	Market Outperform	$22→$10
Aug 12, 2025	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$17→$13
Aug 11, 2025	Oppenheimer	Jay Olson	PT Cut	Outperform	$48→$44
Jul 17, 2025	RBC Capital	Leonid Timashev	PT Cut	Outperform	$32→$25
May 6, 2025	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$15→$17
May 2, 2025	RBC Capital	Gregory Renza	PT Cut	Outperform	$35→$32
May 2, 2025	B. Riley Securities	Kalpit Patel	PT Cut	Neutral	$17→$14
May 2, 2025	JMP Securities	Reni Benjamin	PT Cut	Market Outperform	$26→$22
May 2, 2025	Needham	Ami Fadia	Maintained	Buy	$29
May 1, 2025	Barclays	Peter Lawson	PT Cut	Overweight	$40→$15
Apr 29, 2025	Needham	Ami Fadia	PT Cut	Buy	$30→$29

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $15 to $14.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight and lowers the price target from $13 to $12.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and lowers the price target from $44 to $36.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

RBC Capital analyst Leonid Timashev maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Sector Perform and lowers the price target from $11 to $7.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

Citizens analyst Brett Knoblauch maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outperform and lowers the price target from $12 to $8.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $24 to $15.

Benzinga Newsdesk

Bicycle Therapeutics PLC

Bicycle Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

PRO
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

PRO
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

PRO
Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

Benzinga

Benzinga

Bicycle Therapeutics PLC

Bicycle Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

PROMorgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

PROOppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

PRORBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

PROCitizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

PRONeedham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

PRO
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

PRO
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

PRO
Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15